IL308204A - Anti-nkg2d antibodies and uses thereof - Google Patents

Anti-nkg2d antibodies and uses thereof

Info

Publication number
IL308204A
IL308204A IL308204A IL30820423A IL308204A IL 308204 A IL308204 A IL 308204A IL 308204 A IL308204 A IL 308204A IL 30820423 A IL30820423 A IL 30820423A IL 308204 A IL308204 A IL 308204A
Authority
IL
Israel
Prior art keywords
antibodies against
against nkg2d
nkg2d
antibodies
Prior art date
Application number
IL308204A
Other languages
English (en)
Hebrew (he)
Inventor
Oren Bogin
Liat Dassa
Original Assignee
Immunorizon Ltd
Oren Bogin
Liat Dassa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunorizon Ltd, Oren Bogin, Liat Dassa filed Critical Immunorizon Ltd
Publication of IL308204A publication Critical patent/IL308204A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL308204A 2021-05-04 2022-05-02 Anti-nkg2d antibodies and uses thereof IL308204A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163183635P 2021-05-04 2021-05-04
PCT/IL2022/050453 WO2022234571A2 (en) 2021-05-04 2022-05-02 Anti-nkg2d antibodies and uses thereof

Publications (1)

Publication Number Publication Date
IL308204A true IL308204A (en) 2024-01-01

Family

ID=83932629

Family Applications (1)

Application Number Title Priority Date Filing Date
IL308204A IL308204A (en) 2021-05-04 2022-05-02 Anti-nkg2d antibodies and uses thereof

Country Status (11)

Country Link
US (1) US20240228626A1 (enExample)
EP (1) EP4333889A4 (enExample)
JP (1) JP2024517741A (enExample)
KR (1) KR20240004838A (enExample)
CN (1) CN117396220A (enExample)
AU (1) AU2022269411A1 (enExample)
BR (1) BR112023023090A2 (enExample)
CA (1) CA3217726A1 (enExample)
IL (1) IL308204A (enExample)
MX (1) MX2023013017A (enExample)
WO (1) WO2022234571A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116199777B (zh) * 2021-12-01 2025-01-28 北京免疫方舟医药科技有限公司 抗hNKG2D抗体及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009077483A1 (en) * 2007-12-14 2009-06-25 Novo Nordisk A/S Antibodies against human nkg2d and uses thereof
US9273136B2 (en) * 2008-08-04 2016-03-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human anti-human NKG2D monoclonal antibodies
CN105777907B (zh) * 2010-02-24 2020-03-17 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
EP2995679A4 (en) * 2013-03-11 2016-12-14 Kansai Bunri Sogo Gakuen PROCESS FOR PREPARING MONOCLONAL IGA ANTIBODIES
US20170145086A1 (en) * 2015-11-25 2017-05-25 Visterra, Inc. Antibody molecules to april and uses thereof
WO2018030405A1 (ja) * 2016-08-09 2018-02-15 国立大学法人東京医科歯科大学 Ｈｍｇｂ１に対する抗体、及びそれを含有するアルツハイマー病を治療又は予防するための組成物
CN113811549A (zh) * 2019-02-21 2021-12-17 Xencor股份有限公司 非靶向和靶向性il-10 fc融合蛋白
CN113811546B (zh) * 2019-05-07 2025-03-11 免疫里森公司 前体三特异性抗体构建体及其使用方法
AR119393A1 (es) * 2019-07-15 2021-12-15 Hoffmann La Roche Anticuerpos que se unen a nkg2d
US20210024644A1 (en) * 2019-07-25 2021-01-28 Zomedica Pharmaceuticals Corp. N-cadherin binding molecules and uses thereof
CN116096754A (zh) * 2020-05-04 2023-05-09 免疫里森公司 前体三特异性抗体构建体及其使用方法

Also Published As

Publication number Publication date
EP4333889A2 (en) 2024-03-13
CA3217726A1 (en) 2022-11-10
CN117396220A (zh) 2024-01-12
WO2022234571A2 (en) 2022-11-10
EP4333889A4 (en) 2025-11-12
MX2023013017A (es) 2024-01-18
JP2024517741A (ja) 2024-04-23
KR20240004838A (ko) 2024-01-11
BR112023023090A2 (pt) 2024-01-30
US20240228626A1 (en) 2024-07-11
WO2022234571A3 (en) 2022-12-29
AU2022269411A1 (en) 2023-12-21

Similar Documents

Publication Publication Date Title
IL289354A (en) Anti-cd154 antibodies and uses thereof
EP4085076C0 (en) BCMA-BINDING ANTIBODIES AND THEIR USES
PT3802608T (pt) Anticorpos anti-cd3 e utilizações destes
IL283379A (en) Anti-claudin 18.2 and anti-4-1bb bispecific antibodies and uses thereof
EP3740224A4 (en) ANTI-LILRB ANTIBODIES AND THEIR USES
EP3753953A4 (en) CD47 SINGLE-DOMAIN ANTIBODIES AND ITS USE
EP3904382A4 (en) ANTI-IL-23P19 ANTIBODIES AND USES THEREOF
IL285626A (en) Claudin 6 antibodies and uses thereof
EP4071172A4 (en) ANTI-LILRB1 ANTIBODIES AND ITS USES
EP4025609A4 (en) ANTI-STEAP1 ANTIBODIES AND THEIR USES
IL283875A (en) Anti-il-27 antibodies and uses thereof
EP4359442A4 (en) ANTI-CCR8 ANTIBODIES AND THEIR USES
IL281297A (en) Anti-npr1 antibodies and uses thereof
EP4499707A4 (en) CCR8 ANTIBODIES AND THEIR USES
EP4244255A4 (en) ANTI-TIGIT ANTIBODIES AND THEIR USES
IL291546A (en) Anti-kir3dl3 antibodies and uses thereof
EP4142793A4 (en) ABCB5-SPECIFIC ANTIBODIES AND THEIR USES
EP4132569A4 (en) ANTI-PHF-TAU ANTIBODIES AND USES
EP4126938A4 (en) ANTIBODIES BINDING TO SIGLEC15 AND THEIR USES
IL291280A (en) Anti-cd371 antibodies and uses thereof
IL291550A (en) Anti-il-27 antibodies and uses thereof
IL286803A (en) Anti-tauc3 antibodies and uses thereof
IL288923A (en) Anti-cd47 antibodies and uses thereof
EP4395822A4 (en) ANTI-ACVR2A ANTIBODIES AND THEIR USES
EP4076526A4 (en) Novel ddr1 antibodies and uses thereof